Patents by Inventor Scott Eugene BUCKLIN

Scott Eugene BUCKLIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Vaccine against porcine parvovirus
    Patent number: 10799578
    Abstract: The present invention relates to a porcine parvovirus (PPV) viral protein 2 (VP2) having at amino acid position 228 a glutamic acid residue or a glutamate residue, and/or at amino acid position 414 a serine residue, and/or at amino acid position 419 a glutamine residue, and/or at amino acid position 436 a threonine residue. Further, the present invention relates to immunogenic compositions comprising said PPV viral protein 2 (VP2). Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by PPV infection in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: October 13, 2020
    Inventors: Scott Eugene Bucklin, Troy James Kaiser, Jeremy Kroll, Philip Utley, Eric Martin Vaughn
  • VACCINE AGAINST PORCINE PARVOVIRUS
    Publication number: 20200030438
    Abstract: The present invention relates to a porcine parvovirus (PPV) viral protein 2 (VP2) having at amino acid position 228 a glutamic acid residue or a glutamate residue, and/or at amino acid position 414 a serine residue, and/or at amino acid position 419 a glutamine residue, and/or at amino acid position 436 a threonine residue. Further, the present invention relates to immunogenic compositions comprising said PPV viral protein 2 (VP2). Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by PPV infection in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: October 10, 2019
    Publication date: January 30, 2020
    Inventors: Scott Eugene BUCKLIN, Troy James KAISER, Jeremy KROLL, Philip UTLEY, Eric Martin VAUGHN
  • Vaccine against porcine parvovirus
    Patent number: 10485866
    Abstract: The present invention relates to a porcine parvovirus (PPV) viral protein 2 (VP2) having at amino acid position 228 a glutamic acid residue or a glutamate residue, and/or at amino acid position 414 a serine residue, and/or at amino acid position 419 a glutamine residue, and/or at amino acid position 436 a threonine residue. Further, the present invention relates to immunogenic compositions comprising said PPV viral protein 2 (VP2). Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by PPV infection in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: November 26, 2019
    Inventors: Scott Eugene Bucklin, Troy James Kaiser, Jeremy Kroll, Philip Utley, Eric Martin Vaughn
  • VACCINE AGAINST PORCINE PARVOVIRUS
    Publication number: 20180133309
    Abstract: The present invention relates to a porcine parvovirus (PPV) viral protein 2 (VP2) having at amino acid position 228 a glutamic acid residue or a glutamate residue, and/or at amino acid position 414 a serine residue, and/or at amino acid position 419 a glutamine residue, and/or at amino acid position 436 a threonine residue. Further, the present invention relates to immunogenic compositions comprising said PPV viral protein 2 (VP2). Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by PPV infection in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.
    Type: Application
    Filed: November 2, 2017
    Publication date: May 17, 2018
    Inventors: Scott Eugene BUCKLIN, Troy James KAISER, Jeremy KROLL, Philip UTLEY, Eric Martin VAUGHN